SureTrader SureTrader
Home > Boards > US Listed > Biotechs >

Titan Pharmaceuticals (TTNP)

TTNP RSS Feed
Add TTNP Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator interstate, TRUTH, matthewverymuch, Ppower
Search This Board:
Last Post: 5/29/2015 5:12:25 PM - Followers: 170 - Board type: Free - Posts Today: 0


 






Products


Probuphine®-This study is enrolling participants by invitation only.

Click For Link To ClinicalTrials.gov


*November 20, 2014 -  the study is 100% enrolled. 
   * First patients enrolled on Jul 21, 2014 *                                  * DrKate Glassman-Beebe- Executive Vice President and Chief Development Officer-Titan Pharmaceuticals

Click For cnn.com Link 


Sponsor:

Braeburn Pharmaceuticals


ClinicalTrials.gov Identifier:
Information provided by (Responsible Party):
NCT02180659
First received: July 1, 2014
Last updated: July 8, 2014
Last verified: July 2014
Braeburn Pharmaceuticals









Probuphine Graphic

 

 

 

Continuous Drug Delivery Technology

 

The continuous drug delivery system consists of a small, solid rod made from a mixture of ethylene-vinyl acetate (“EVA”) and a drug substance. The resulting product is a solid matrix that is placed subcutaneously, normally in the inner part of the upper arm in a simple office procedure, and is removed in a similar manner at the end of the treatment period. The drug substance is released slowly, at continuous levels, through the process of dissolution. This results in a stable blood level similar to intravenous administration. Such long-term, linear release characteristics are generally desirable as this avoids peak and trough level dosing that poses problems for many Central Nervous System (“CNS”) and other disease settings.

This continuous drug delivery technology was developed to address the need for a simple, practical method to potentially provide continuous drug administration on an outpatient basis over extended periods of up to 6-12 months. In addition to Probuphine, which is the first product to complete clinical testing that has utilized this proprietary continuous drug delivery technology, Titan has conducted initial non-clinical studies with long-term delivery of dopamine agonists demonstrating the potential of this product in the treatment of Parkinson’s disease in non-clinical models of the disease.

 



Fanapt® (iloperidone)

 

Fanapt (iloperidone) is an atypical antipsychotic approved by the FDA for the treatment of schizophrenia currently being marketed by Novartis Pharma AG (“Novartis”) in the U.S. Titan is entitled to a royalty of 8-10% of net sales of Fanapt under a sublicense agreement with Novartis that is based on a U.S. patent which expires in October 2016 (does not include a possible six-month pediatric extension).

Titan has entered into several agreements with Deerfield Management LP (“Deerfield”), which entitle Deerfield to most of the future royalty revenues related to Fanapt in exchange for cash and debt considerations, the proceeds of which have been used to advance the development of Probuphine and for general corporate purposes. Titan has retained a portion of the royalty revenue from net sales of Fanapt in excess of specified annual threshold levels; however, based on sales levels to date, it is unlikely that Titan will retain any revenue from Fanapt in the next several years, if ever. Titan does not incur any ongoing expenses associated with this product.




Company Overview



Titan Pharmaceuticals, Inc is a biopharmaceutical company focused in the development of products for the treatment of central nervous system (CNS) diseases. Titan's first out licensed product, Fanapt® (iloperidone) is an atypical antipsychotic approved in the U.S. in May 2009 for the treatment of schizophrenia in adult patients. It is currently marketed in the U.S. by Novartis Pharma, AG, and Titan is entitled to receive 8-10% of global annual sales as royalty revenue for the term of the licensed patents.

 

Titan's second product, Probuphine, is nearing completion of the Phase 3 clinical development program in the treatment of opioid addiction. Probuphine is a novel, subcutaneous implant formulation of buprenorphine designed to deliver six months of medication following single treatment. This product has already demonstrated strong positive results in the first controlled Phase 3 study for the treatment of opioid addiction. The confirmatory Phase 3 study is currently being conducted at 20 sites in the U.S., and the results of this study are expected in Q2, 2011. Additional information on the Probuphine program is available in the PRODUCTS section of this website.

 

The Company's common stock is traded on the OTC Bulletin Board Markets ([TTNP.OB] www.otcbb.com) quotations system. For further information please contact info@titanpharm.com

 

Management Team

President
Sunil Bhonsle, M.B.A.

Executive Vice President and Chief Development Officer

Katherine L. Beebe, Ph.D.

Executive Chairman

Marc Rubin, M.D.

 



Board of Directors

 
 
  






 

Strategic Alliances


In December 2012, Titan entered into a license agreement with Braeburn Pharmaceuticals Sprl (“Braeburn”) that grants Braeburn exclusive commercialization rights to Probuphine® in the United States and Canada. Titan received a non-refundable up-front license fee of $15.75 million and will receive a $50 million milestone payment upon the approval of the NDA by the FDA. Additionally, Titan will be eligible to receive up to $130 million upon achievement of specified sales milestones and up to $35 million in regulatory milestones in the event of future NDA submissions and approvals for additional indications, including chronic pain. Titan will receive tiered royalties on net sales of Probuphine ranging from the mid-teens to the low twenties.

 





Product Overview

The investigational products are at various stages of development as listed below.

Titan Pharmaceuticals Products

 


 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
TTNP
Current Price
Volume:
Bid Ask Day's Range
Wiki
TTNP News: Quarterly Report (10-q) 05/13/2015 02:47:57 PM
TTNP News: Current Report Filing (8-k) 04/28/2015 04:27:49 PM
TTNP News: TITAN PHARMACEUTICALS (TTNP) SHAREHOLDER ALERT – Andrews & Springer LLC Is Investigating Titan Pharmaceuticals, Inc. For Po... 04/08/2015 08:13:00 AM
TTNP News: Annual Report (10-k) 03/31/2015 12:42:08 PM
TTNP News: Statement of Changes in Beneficial Ownership (4) 03/18/2015 07:48:51 PM
PostSubject
#3684  Sticky Note ****Addicts DESPERATELY Waiting For A Lifesaver**** TRUTH 09/27/14 11:41:37 AM
#5307   .titan could easily break a buck in a TRUTH 05/29/15 05:12:25 PM
#5306   And no harm done Truth! Definitely appreciate all bryansyy 05/29/15 05:09:08 PM
#5305   So truth my thinking goes like this.June first turks 05/29/15 05:06:56 PM
#5304   Meant no harm.... TRUTH 05/29/15 05:00:29 PM
#5303   Only those looking for quick buck where let TRUTH 05/29/15 04:55:53 PM
#5302   It's just that your username was just created bryansyy 05/29/15 04:53:30 PM
#5301   Did just as expected, .80 for beginning of Rentier 05/29/15 04:51:48 PM
#5300   never does what is expected but the unexpected TRUTH 05/29/15 04:35:34 PM
#5299   Very very strange stock, never does what is turks 05/29/15 04:27:24 PM
#5298   Tomorrow a buck, Monday is june first TRUTH 05/29/15 03:55:27 PM
#5297   As do i...back to even for about 18 matthewverymuch 05/29/15 03:29:28 PM
#5296   I just hope we hold .80 for the week interstate 05/29/15 03:20:50 PM
#5295   All investors are not created equal.... TRUTH 05/29/15 03:19:55 PM
#5294   Doubt it. Retail investors in OTC stocks interstate 05/29/15 03:14:52 PM
#5293   Market Makers are shorting small OTC companies in TRUTH 05/29/15 03:10:31 PM
#5292   I vote in elections, knowing my vote only matthewverymuch 05/29/15 02:35:15 PM
#5291   Yes but our shares in the grand scheme interstate 05/29/15 02:32:17 PM
#5290   Shareholders get a vote either in person or matthewverymuch 05/29/15 02:08:26 PM
#5289   Ha Ha Ha... That was a good one. interstate 05/29/15 01:58:37 PM
#5288   Do we get a vote on that? matthewverymuch 05/29/15 01:53:10 PM
#5287   If approved... I see them being bought out. interstate 05/29/15 01:31:35 PM
#5286   Well, define "the future." Looking in my Doctor Detroit 05/29/15 12:28:29 PM
#5285   Sure why not,need some laughts or maybe not,but turks 05/29/15 11:22:21 AM
#5284   A buck, huh? Haha matthewverymuch 05/29/15 10:46:56 AM
#5283   Makes sense. The link i shared about biotech matthewverymuch 05/29/15 10:38:10 AM
#5282   Sorry... it is 2.72...lol interstate 05/29/15 10:12:55 AM
#5281   Seems like an odd price... matthewverymuch 05/29/15 09:40:33 AM
#5280   Good job, truth TRUTH 05/29/15 09:21:22 AM
#5279   Pretty sure it is a short, cover, and matthewverymuch 05/29/15 09:12:48 AM
#5278   It will be interesting to see what the interstate 05/29/15 08:59:46 AM
#5277   I just cannot not believe that the short TRUTH 05/29/15 08:55:26 AM
#5276   That added up to almost 2.43 million shares interstate 05/29/15 08:46:15 AM
#5275   If approved... 2.71 is my min. interstate 05/29/15 08:38:41 AM
#5274   There's Probuphine to consider,with potential European talks later TRUTH 05/29/15 06:57:25 AM
#5273   The short selling data doesn't lie.... TRUTH 05/29/15 06:29:55 AM
#5272   Interesting, you've been around that long too. shadolane 05/29/15 06:15:12 AM
#5271   Reality check. I've only seen an "analysis" ekmey 05/28/15 11:17:53 PM
#5270   Got your pm. Thanks matthewverymuch 05/28/15 10:57:43 PM
#5269   Look at otc short report for ttnp....the daily matthewverymuch 05/28/15 10:42:18 PM
#5268   Short buying can not be 50% each day. interstate 05/28/15 10:22:35 PM
#5267   +100 and two thumbs up... Once again I interstate 05/28/15 10:20:31 PM
#5266   Well, waddya know!? Good job, truth matthewverymuch 05/28/15 08:52:59 PM
#5265   ****Sunil Bhonsle Responds Via Voicemail And Answers Call**** TRUTH 05/28/15 08:13:49 PM
#5264   54% short today... matthewverymuch 05/28/15 06:44:38 PM
#5263   Tomorrow a buck, Monday is june first June turks 05/28/15 05:52:56 PM
#5262   Senate Bill Would Dramatically Alter Treatment For Heroin Addiction TRUTH 05/28/15 04:46:19 PM
#5261   Looking for the 52 week high next week IMO interstate 05/28/15 04:43:01 PM
#5260   Lookin good in here taubytaub 05/28/15 04:07:01 PM
#5259   You have made an excellent point, mr truth. matthewverymuch 05/28/15 03:02:07 PM
#5258   we all know that we're not dealing with TRUTH 05/28/15 02:52:37 PM
PostSubject